What You Should Know:
– CureMetrix, an innovator in AI-driven mammography solutions, has partnered with SimonMed Imaging, a prominent provider of outpatient medical imaging services in the United States.
– The strategic collaboration will bring CureMetrix’s cutting-edge AI technology, cmAngio, to SimonMed Imaging’s extensive network of facilities across the nation.
cmAngio: Enhancing Breast Cancer Detection with AI
cmAngio is an FDA-cleared AI-powered software designed to analyze mammograms and detect potential indicators of breast cancer, including Breast Arterial Calcifications (BAC). The software seamlessly integrates with existing mammography systems, providing radiologists with an additional layer of analysis to aid in the early detection and diagnosis of breast cancer.
Key Features and benefits of cmAngio include:
- AI-Powered Accuracy: cmAngio leverages advanced AI algorithms to identify and localize BAC with exceptional precision.
- Seamless Integration: The software seamlessly integrates with both full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) systems, making it easily adaptable to various clinical settings.
- Enhanced Efficiency: cmAngio streamlines the mammography analysis process, assisting radiologists in efficiently identifying potential areas of concern.
- Improved Patient Outcomes: By aiding in the early detection of breast cancer, cmAngio contributes to improved patient outcomes and survival rates.
“At SimonMed Imaging, our motto ‘See Tomorrow Today’ reflects our belief that new technology can help provide more accurate diagnoses, but it must also be readily available and affordable to make a real impact,” said Dr. John Simon, Chief Executive Officer at SimonMed Imaging. “Our partnership with CureMetrix and the integration of cmAngio is a testament to this mission. By combining innovative tools with the expertise of our subspecialty-trained radiologists, we continue to deliver the highest quality care in a cost-effective and service-oriented environment, empowering better health outcomes for our patients.”
